|
|
|
|
|
Ibandronate: profile and news
Bondronat Achieving Better Outcomes in Metastatic Breast Cancer ... Feb 21, 2006 Bisphosphonate Safety Evaluation Shows General Safety: Presented ... Feb 21, 2006 Adjuvant Bondronat Therapy Plays Important Role in Prevention of ... Feb 20, 2006 Older Men Surviving Heart Attack at Higher Risk of Osteoporosis Feb 21, 2006 Xeloda Expands Options in Adjuvant Treatment of Breast Cancer ... Feb 21, 2006 Scots get new drug to fight against bone disease Feb 13, 2006 It is Predicted in the Next Ten Years the Demand for Drugs to ... Feb 3, 2006 Scottish Medicines Consortium Approves Bonviva® - Scottish Women ... Feb 14, 2006 FDA Approves First IV Treatment for Postmenopausal Osteoporosis ... Jan 9, 2006 European positive opinion for first quarterly IV injection for Jan 27, 2006 FDA approves first quarterly IV injection for postmenopausal ... Jan 9, 2006 It is Predicted in the Next Ten Years the Demand for Drugs to ... Feb 3, 2006 Boniva for injection cleared in USA Jan 9, 2006 Osteoporosis Information Now Online at NIHSeniorHealth Jan 27, 2006 FDA Approves First IV Treatment for Postmenopausal Osteoporosis ... Jan 6, 2006 Companies say FDA approves IV version of postmenopausal ... Jan 9, 2006 Business Briefing Jan 7, 2006 Bonviva intravenous injection for postmenopausal osteoporosis ... Nov 19, 2005 Long-Term Use of Bisphosphonates and Osteonecrosis of the Jaw ... Nov 30, 2005 GlaxoSmithKline, Roche say long term data positive on injectable ... Nov 16, 2005 Many Patients with Osteoporosis Do Not Continue Their ... Nov 21, 2005 Two-Year MOBILE Data Show Once-Monthly Oral Ibandronate to be ... Oct 6, 2005 Monthly bone-building pill remedies osteoporosis Oct 6, 2005 Study Shows Women With Postmenopausal Osteoporosis Prefer New Once ... Sep 26, 2005 Study Shows Women Prefer Once-Monthly Osteoporosis Medicine Over a ... Sep 26, 2005 Roche and GSK Announce Head-to-Head Study of Osteoporosis ... Sep 26, 2005 International Approvals: Bonviva, Once-Daily Tramadol ... Sep 12, 2005 Once-monthly Oral Bonviva Approved for Postmenopausal Osteoporosis ... Sep 19, 2005 Launch of First Once-Monthly Tablet Aims to Offer More Convenience ... Sep 20, 2005 GSK, Roche to test osteoporosis drug Sep 26, 2005 Once-Monthly Oral Bonviva Approved for Postmenopausal Osteoporosis ... 08 Sep 2005 Roche and GSK’s Intravenous Formulations Show Potential Jul 6, 2005 Chicagoland: Bobby Labonte preview Jul 6, 2005 Loose Wheel Costs Labonte Top-10 at Chicagoland Jul 10, 2005 Joe Gibbs Racing Breezes Through Jul 14, 2005 Other information Indication For the treatment and prevention of osteoporosis in postmenopausal women. Also used to treat tumor induced hypercalemia. Pharmacology Ibandronate is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. Ibandronate is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Mechanism Of Action The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Ibandronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass. Drug Category Antiresorptives; Bisphosphonates; Antihypocalcemic Agents; ATC:M05BA06 Brand Names/Synonyms Boniva; Ibandronate; Ibandronate Sodium; Ibandronate Sodium Monohydrate; Ibandronic Acid; Ibandronic Acid [Ban:Inn]; None Dosage Forms LIQUID Absorption Poorly absorbed (oral absorption is about 1% of what IV absorption is) Interactions Interactions for Ibandronate: Calcium Supplements/Antacids Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate. Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins). H2 Blockers and Proton Pump Inhibitors (PPIs) Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs). Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate was similar to that in placebo-treated patients. Similarly, of over 1600 patients enrolled in a study comparing once-monthly with daily dosing regimens of ibandronate, 14% of patients used anti-peptic agents. Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily. Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs) In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients. Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%). Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients. The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%). However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate. Drug/Laboratory Test Interactions Bisphosphonates are known to interfere with the use of bone-imaging agents. Specific studies with ibandronate have not been performed. Chemical IUPAC Name morpholin-4-yl-[4-(trifluoromethyl)phenyl]-methanone Chemical Formula C9H23NO7P2 Half Life 10-60 hours Drug Type Approved Drug # Accession No APRD00231 CAS Registry Number 138926-19-9 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |